NR3C2 and acute kidney injury: In animal models, endothelin receptor antagonists, PPAR agonists, phosphodiesterase inhibitors, and novel mineralocorticoid receptor blockers have demonstrated possible nephroprotective effects against AKI and may represent future therapeutic strategies for the prevention and treatment of AKI and CKD (123, 139–142).